Search
Borage oil
go.drugbank.com/drugs/DB11238ApprovedBorage oil, or borage seed oil, is a rich source of gamma-linolenic acid (GLA) that is obtained from the seeds of the Borago officinalis (borage). … GLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series
GnRH pharmaccine
go.drugbank.com/drugs/DB05815ExperimentalThe pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalIPL 576,092 has previously been investigated as a treatment for asthma. … HMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid.
Elsulfavirine
go.drugbank.com/drugs/DB14929InvestigationalElsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigationalTafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059] … [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways.
Pomaglumetad methionil
go.drugbank.com/drugs/DB05096InvestigationalLY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed.
Dapoxetine
go.drugbank.com/drugs/DB04884InvestigationalAlza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.
Chlorphenesin
go.drugbank.com/drugs/DB00856ApprovedCategories: Antifungals for Topical Use, Antifungals for Dermatological Use